X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Wockhardt with Torrent Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT LTD. vs TORRENT PHARMA - Comparison Results

WOCKHARDT LTD.    Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

TORRENT PHARMA 
   Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT LTD. TORRENT PHARMA WOCKHARDT LTD./
TORRENT PHARMA
 
P/E (TTM) x -11.6 37.2 - View Chart
P/BV x 2.3 5.8 40.1% View Chart
Dividend Yield % 1.4 0.9 151.0%  

Financials

 WOCKHARDT LTD.   TORRENT PHARMA
EQUITY SHARE DATA
    WOCKHARDT LTD.
Mar-17
TORRENT PHARMA
Mar-17
WOCKHARDT LTD./
TORRENT PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1291,768 63.9%   
Low Rs6271,186 52.9%   
Sales per share (Unadj.) Rs363.1346.1 104.9%  
Earnings per share (Unadj.) Rs-20.455.2 -37.1%  
Cash flow per share (Unadj.) Rs-7.073.3 -9.5%  
Dividends per share (Unadj.) Rs10.0014.00 71.4%  
Dividend yield (eoy) %1.10.9 120.1%  
Book value per share (Unadj.) Rs301.8257.1 117.4%  
Shares outstanding (eoy) m110.55169.22 65.3%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x2.44.3 56.7%   
Avg P/E ratio x-42.926.8 -160.4%  
P/CF ratio (eoy) x-125.920.1 -624.9%  
Price / Book Value ratio x2.95.7 50.6%  
Dividend payout %-48.925.4 -192.7%   
Avg Mkt Cap Rs m97,063249,887 38.8%   
No. of employees `0006.811.8 57.4%   
Total wages/salary Rs m9,6659,934 97.3%   
Avg. sales/employee Rs Th5,931.84,971.5 119.3%   
Avg. wages/employee Rs Th1,428.1843.2 169.4%   
Avg. net profit/employee Rs Th-334.0792.4 -42.1%   
INCOME DATA
Net Sales Rs m40,14658,569 68.5%  
Other income Rs m1,1432,233 51.2%   
Total revenues Rs m41,28960,802 67.9%   
Gross profit Rs m12813,773 0.9%  
Depreciation Rs m1,4893,069 48.5%   
Interest Rs m2,2532,056 109.6%   
Profit before tax Rs m-2,47210,881 -22.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-2111,545 -13.7%   
Profit after tax Rs m-2,2609,336 -24.2%  
Gross profit margin %0.323.5 1.4%  
Effective tax rate %8.514.2 60.2%   
Net profit margin %-5.615.9 -35.3%  
BALANCE SHEET DATA
Current assets Rs m46,16053,841 85.7%   
Current liabilities Rs m19,25831,612 60.9%   
Net working cap to sales %67.038.0 176.6%  
Current ratio x2.41.7 140.7%  
Inventory Days Days10197 103.7%  
Debtors Days Days9484 112.3%  
Net fixed assets Rs m40,16542,079 95.5%   
Share capital Rs m553846 65.3%   
"Free" reserves Rs m32,81442,655 76.9%   
Net worth Rs m33,36743,501 76.7%   
Long term debt Rs m31,90322,408 142.4%   
Total assets Rs m89,687101,250 88.6%  
Interest coverage x-0.16.3 -1.5%   
Debt to equity ratio x1.00.5 185.6%  
Sales to assets ratio x0.40.6 77.4%   
Return on assets %011.3 -0.1%  
Return on equity %-6.821.5 -31.6%  
Return on capital %-0.319.6 -1.7%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,12120,066 45.5%   
Fx outflow Rs m2,1335,304 40.2%   
Net fx Rs m6,98814,762 47.3%   
CASH FLOW
From Operations Rs m-2,69510,127 -26.6%  
From Investments Rs m-6,863-7,869 87.2%  
From Financial Activity Rs m12,545-1,918 -654.1%  
Net Cashflow Rs m3,010212 1,423.3%  

Share Holding

Indian Promoters % 74.5 71.5 104.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 2.3 7.0 32.8%  
FIIs % 7.7 12.6 61.1%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 8.8 175.0%  
Shareholders   67,757 26,511 255.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT LTD. With:   PLETHICO PHARMA  BIOCON LTD  UNICHEM LAB  ALKEM LABORATORIES  AJANTA PHARMA  

Compare WOCKHARDT LTD. With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day in Green; Metal Stocks Top Gainers(Closing)

After opening the day in green, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

TORRENT PHARMA Announces Quarterly Results (4QFY18); Net Profit Up 10.7%

Jun 1, 2018 | Updated on Jun 1, 2018

For the quarter ended March 2018, TORRENT PHARMA has posted a net profit of Rs 2 bn (up 10.7% YoY). Sales on the other hand came in at Rs 17 bn (up 20.1% YoY). Read on for a complete analysis of TORRENT PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

After Vakrangee and Manpasand, More Auditors May Soon Resign. To Protect Your Wealth, Avoid these Stocks(The 5 Minute Wrapup)

Jun 8, 2018

The change in auditing regulations can bring a big change in corporate governance behaviour in the mid and small-cap space.

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Is Data Pointing Towards a Revival in the FMCG Sector?(Sector Info)

Jun 8, 2018

After several quarters of stress in the aftermath of demonetisation and the rollout of GST, this data is pointing towards revival in the India's rural FMCG industry.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT LTD. SHARE PRICE


Jun 20, 2018 (Close)

TRACK WOCKHARDT LTD.

  • Track your investment in WOCKHARDT LTD. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON WOCKHARDT LTD.

WOCKHARDT LTD. - WYETH LTD COMPARISON

COMPARE WOCKHARDT LTD. WITH

MARKET STATS